| __timestamp | ADMA Biologics, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9517014 | 19586000 |
| Thursday, January 1, 2015 | 7015946 | 29135000 |
| Friday, January 1, 2016 | 7688238 | 42791000 |
| Sunday, January 1, 2017 | 6229587 | 49577000 |
| Monday, January 1, 2018 | 3926120 | 89209000 |
| Tuesday, January 1, 2019 | 2343848 | 69099000 |
| Wednesday, January 1, 2020 | 5907013 | 75961000 |
| Friday, January 1, 2021 | 3646060 | 90467000 |
| Saturday, January 1, 2022 | 3613764 | 74552000 |
| Sunday, January 1, 2023 | 3300000 | 91593000 |
Unleashing insights
In the competitive world of biopharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, ADMA Biologics, Inc. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Supernus Pharmaceuticals consistently outspent ADMA Biologics, with R&D expenses peaking at approximately $91.6 million in 2023, a staggering 370% increase from 2014. In contrast, ADMA Biologics' R&D spending showed a downward trend, decreasing by about 65% over the same period, ending at around $3.3 million in 2023. This divergence highlights Supernus Pharmaceuticals' aggressive pursuit of innovation, while ADMA Biologics appears to be more conservative in its R&D investments. As the biopharma landscape evolves, these spending patterns may significantly influence each company's future growth and market position.
Research and Development Investment: Pfizer Inc. vs Supernus Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Comparing Innovation Spending: Grifols, S.A. and ADMA Biologics, Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Research and Development Investment: ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for ADMA Biologics, Inc. and Xencor, Inc.
Ultragenyx Pharmaceutical Inc. or Supernus Pharmaceuticals, Inc.: Who Invests More in Innovation?
CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Catalyst Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.